Vutisiri VeerasarnPramook PhromratanapongseNan SuntornpongVicharn LorvidhayaVimol SukthomyaImjai ChitapanaruxChanawat TesavibulThiti SwangsilpaCholakiet KhorprasertKanjana ShotelersukYongyut KongthanaratApichart PanichevalukSunanta ChiewvitPawana PusuwanMonreudee AekmahachaiSamart RatchadaraSasitorn SirilipocheYuttana SaengsudaMahidol UniversityPramongkutklao HospitalChiang Mai UniversityChulalongkorn UniversityRajavithi Hospital2018-08-202018-08-202006-12-01Journal of the Medical Association of Thailand. Vol.89, No.12 (2006), 2056-206701252208012522082-s2.0-33845651416https://repository.li.mahidol.ac.th/handle/20.500.14594/23462Background: Amifostine has a potential role for salivary gland protection in head and neck cancer patients who had radiotherapy. Material and Method: Sixty-seven head and neck cancer patients were randomized to receive radiotherapy or radiotherapy plus Amifostine. The efficacy of the treatment was determined by a questionnaire evaluating dryness of mouth and the oral comfort, the RTOG/EORTC acute/late radiation morbidity scoring criteria, collection of the whole saliva and the 99mTc-pertecnetate scintigraphy of the salivary glands. Results: Amifostine significantly reduced the mean questionnaire scores from 6.49 to 3.73, the incidence of grade ≥ 2 mucositis from 75% to 36% and acute xerostomia from 82% to 39%. The salivary gland function returned to normal at a rate of 36.3% in the Amifostine group versus 9.1% in the control group. Conclusion: Amifostine is effective in reducing the incidence and severity of acute mucositis, acute and late xerostomia in head and neck cancer patients.Mahidol UniversityMedicineArticleSCOPUS